Polish Maker of Sandoz Biosimilar Can’t Evade Biogen Patent Suit

The Polish manufacturer of Sandoz’s biosimilar version of Biogen’s Tysabri failed to convince a federal judge in Delaware that it can’t be held liable for the alleged infringement of patents for the lucrative multiple sclerosis treatment.

Judge Gregory B. Williams issued an order Tuesday in the US District Court for the District of Delaware denying Polpharma Biologics SA’s request to dismiss Biogen Inc.'s second amended complaint against it. No redacted version of his opinion, issued concurrently under seal, is yet available.

• Polpharma argued in its March 2023 supporting brief that it wasn’t properly named as a defendant because it didn’t ...